The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
RETRACTED ARTICLE: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials
Open accessAbstract
BACKGROUND: Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Here we evaluate six phase 2 trials in a pooled analysis to determine the study design for phase 3 trials of MDMA-assisted psychotherapy for PTSD. METHODS: Six randomized, double-blind, controlled clinical trials at five study sites were conducted from April 2004 to February 2017. Active doses of MDMA (75-125 mg, n = 72) or placebo/control doses (0-40 mg, n = 31) were administered to individuals with PTSD during manualized psychotherapy sessions in two or three 8-h sessions spaced a month apart. Three non-drug 90-min therapy sessions preceded the first MDMA exposure, and three to four followed each experimental session. RESULTS: After two blinded experimental sessions, the active group had significantly greater reductions in CAPS-IV total scores from baseline than the control group [MMRM estimated mean difference (SE) between groups - 22.0 (5.17), P < 0.001]. The between-group Cohen's d effect size was 0.8, indicating a large treatment effect. After two experimental sessions, more participants in the active group (54.2%) did not meet CAPS-IV PTSD diagnostic criteria than the control group (22.6%). Depression symptom improvement on the BDI-II was greatest for the active group compared to the control group, although only trended towards significant group differences [MMRM, estimated mean difference (SE) between groups - 6.0 (3.03), P = 0.053]. All doses of MDMA were well tolerated, with some expected reactions occurring at greater frequency for the active MDMA group during experimental sessions and the 7 days following. CONCLUSIONS: MDMA-assisted psychotherapy was efficacious and well tolerated in a large sample of adults with PTSD. These studies supported expansion into phase 3 trials and led to FDA granting Breakthrough Therapy designation for this promising treatment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00090064, NCT00353938, NCT01958593, NCT01211405, NCT01689740, NCT01793610.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The effect sizes for improvements in PTSD and common co-occurring conditions in this pilot study were greater than those found with individually delivered MDMA-facilitated psychotherapy for PTSD (see Mithoefer et al., 2019 for pooled pre- to post-treatment effect in six phase 2 RCTs of approximately d = 1.20).”
From MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial (2020) · cites this paper as Mithoefer et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MDMA-AT has also been most extensively tested in the treatment of post-traumatic stress disorder (PTSD) and has shown to result in large effect size differences compared to placebo controls in Phase II and Phase 3 trials (18–21).”
From MDMA-Assisted Therapy as a Means to Alter Affective, Cognitive, Behavioral, and Neurological Systems Underlying Social Dysfunction in Social Anxiety Disorder (2021) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“MDMA (3,4-methylenedioxymethamphetamine) has been used to facilitate an individual therapy for PTSD.”
From MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial (2020) · cites this paper as Mithoefer et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“In addition, both phase II (19) and the existing phase 3 study (20) suggest excellent safety and low abuse potential when MDMA is used under controlled conditions.”
In the citing paper
“Pooled analysis of six phase 2 trials of MDMA-assisted therapy for PTSD have now shown promising safety and efficacy findings15.”
From MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (2021) · cites this paper as [15]
In the citing paper
“Although low-dose MDMA improved blinding in phase 2 studies, it led to decreased effectiveness compared with an inactive placebo in a PTSD population, making it easier to detect a difference between the active and comparator groups15.”
From MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients
Beck, A. T., Steer, R. A., Ball, R., & Ranieri, W. F. (1996) · Journal of Personality Assessment · doi:10.1207/s15327752jpa6703_13 · Cited by 5,965
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
The development of a Clinician-Administered PTSD Scale
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995) · Journal of Traumatic Stress · doi:10.1002/jts.2490080106 · Cited by 5,024
Paced Auditory Serial-Addition Task: A Measure of Recovery from Concussion
Gronwall, D. M. A. (1977) · Perceptual and Motor Skills · doi:10.2466/pms.1977.44.2.367 · Cited by 2,395 · cited 2×
“Participants completed the PacedAuditory Serial Addition Task (PASAT) (Gronwall 1977) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (Randolph 1998) at baseline and 2-month follow-up to determine whether changes in cognitive function had occurred after two sessions…”
MethodA Multidimensional Meta-Analysis of Psychotherapy for PTSD
Bradley, R., Greene, J., Russ, E., Dutra, L., & Westen, D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.2.214 · Cited by 1,938
Kilpatrick, D. G., Resnick, H. S., Milanak, M. E., Miller, M. W., Keyes, K. M., & Friedman, M. J. (2013) · Journal of Traumatic Stress · doi:10.1002/jts.21848 · Cited by 1,929
Clinician-administered PTSD scale: A review of the first ten years of research
Weathers, F. W., Keane, T. M., & Davidson, J. R. T. (2001) · Depression and Anxiety · doi:10.1002/da.1029 · Cited by 1,903
Posttraumatic stress disorder in the world mental health surveys
Koenen, K. C., Ratanatharathorn, A., Ng, L., McLaughlin, K. A., Bromet, E. J., Stein, D. J., Karam, E. G., Meron Ruscio, A., Benjet, C., Scott, K., et al. (2017) · Psychological Medicine · doi:10.1017/s0033291717000708 · Cited by 1,453
(2007) · Medical Entomology and Zoology · Cited by 1,118
Prolonged Exposure Therapy for PTSD: Therapist Guide: Emotional processing of traumatic experiences
Foa, E. B., Hembree, E., & Rothbaum, B. (2007) · doi:10.1093/med:psych/9780195308501.001.0001 · Cited by 1,050
Research works printed but not linked: 2
- Grof S (2001) LSD psychotherapy, 4th edn. Multidisciplinary Association for Psychedelic Studies, Ben Lomond, CA
- Kadel R & Kip K (2012). A SAS macro to compute effect size (Cohen’s d) and its confidence interval from raw survey data. In Proceedings of the Annual Southeast SAS Users Group Conference
Cited by
Sorted by citations
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G., M., Garas, W., Paleos, C., Gorman, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01336-3 · Cited by 1,004
MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial
Mitchell, J. M., Ot’alora G., M., van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., Paleos, C., Nicholas, C. R., Quevedo, S., Balliett, B., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02565-4 · Cited by 455
Andersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347
Reviewing the Potential of Psychedelics for the Treatment of PTSD
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa018 · Cited by 260
Gregorio, D. D., Aguilar‐Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1659-20.2020 · Cited by 279
Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0569-3 · Cited by 247
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Aday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06123-7 · Cited by 237
Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review
Burback, L., Brémault‐Phillips, S., Nijdam, M. J., McFARLANE, A. C., & Vermetten, E. H. G. J. M. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230428091433 · Cited by 251
A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy
Luoma, J. B., Chwyl, C., Bathje, G. J., Davis, A. K., & Lancelotta, R. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1769878 · Cited by 212
Walsh, Z., Mollaahmetoğlu, Ö. M., Rootman, J. M., Golsof, S., Keeler, J. L., Marsh, B., Nutt, D., & Morgan, C. J. A. (2021) · BJPsych Open · doi:10.1192/bjo.2021.1061 · Cited by 204
Breeksema, J. J., Kuin, B. W., Kamphuis, J., van den Brink, W., Vermetten, E., & Schoevers, R. A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221116926 · Cited by 178
“Two RCTs systematically assessed AEs (Mitchell et al., 2021; Mithoefer et al., 2019), another study employed the UKU scale of secondary effects; this was the only study reporting AE severity (Oehen et al.”
BackgroundResultInfluentialWolfson, P. E., Andries, J., Feduccia, A. A., Jerome, L., Wang, J. B., Williams, E., Carlin, S. C., Sola, E., Hamilton, S., Yazar-Klosinski, B., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75706-1 · Cited by 169
Feduccia, A. A., Jerome, L., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., & Doblin, R. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00650 · Cited by 172
Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions
Cavarra, M., Falzone, A., Ramaekers, J. G., Kuypers, K. P. C., & Mento, C. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.887255 · Cited by 171
Jerome, L., Feduccia, A. A., Wang, J. B., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., & Doblin, R. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05548-2 · Cited by 159
RetractedYao, Y., Guo, D., Lu, T., Liu, F.-L., Huang, S., Diao, M.-Q., Li, S., Zhang, X.-J., Kosten, T. R., Shi, J., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115886 · Cited by 162
Smith, K. W., Sicignano, D. J., Hernández, A. V., & White, C. M. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1995 · Cited by 147
Serotonin toxicity of serotonergic psychedelics
Malcolm, B., & Thomas, K. (2022) · Psychopharmacology · doi:10.1007/s00213-021-05876-x · Cited by 138
Sessa, B., Higbed, L., O’Brien, S., Durant, C. F., Sakal, C., Titheradge, D., Williams, T. M., Rose‐Morris, A., Brew-Girard, E., Burrows, S., et al. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121991792 · Cited by 149
Agin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00018 · Cited by 124
Correll, C. U., Solmi, M., Cortese, S., D, M. F. M., Højlund, M., KRAEMER, H. C., McIntyre, R. S., Pine, D. S., Schneider, L. S. S., & Kane, J. M. (2023) · World Psychiatry · doi:10.1002/wps.21056 · Cited by 115
Psychedelic therapy in the treatment of addiction: the past, present and future
Zafar, R. R., Siegel, M., Harding, R., Barba, T., Agnorelli, C., Suseelan, S., Roseman, L., Wall, M. B., Nutt, D., & Erritzøe, D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1183740 · Cited by 113
Chi, T., & Gold, J. A. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116715 · Cited by 95
Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1772054 · Cited by 94
MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G, M., Garas, W., Paleos, C., Gorman, I., et al. (2023) · Focus · doi:10.1176/appi.focus.23021011 · Cited by 93
Self-citationMonson, C. M., Wagner, A. C., Mithoefer, A. T., Liebman, R. E., Feduccia, A. A., Jerome, L., Yazar-Klosinski, B., Emerson, A., Doblin, R., & Mithoefer, M. C. (2020) · European Journal of Psychotraumatology · doi:10.1080/20008198.2020.1840123 · Cited by 96
“MDMA has more recently been studied to facilitate an individual therapy for PTSD (Mithoefer et al., 2019).”
BackgroundInfluentialBahji, A., Forsyth, A., Groll, D., & Hawken, E. R. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109735 · Cited by 88
Brewerton, T. D., Wang, J. B., Lafrance, A., Pamplin, C., Mithoefer, M., Yazar-Klosinki, B., Emerson, A., & Doblin, R. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.03.008 · Cited by 86
Psilocybin and MDMA for the treatment of trauma-related psychopathology
Bird, C., Modlin, N. L., & Rucker, J. (2021) · International Review of Psychiatry · doi:10.1080/09540261.2021.1919062 · Cited by 94
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 92
Acute subjective effects in LSD- and MDMA-assisted psychotherapy
Schmid, Y., Gasser, P., Oehen, P., & Liechti, M. E. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959604 · Cited by 85
Lea, T., Amada, N. M., Jungaberle, H., Schecke, H., Scherbaum, N., & Klein, M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05477-0 · Cited by 76
Thrul, J., & Garcia‐Romeu, A. (2021) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2021.1897331 · Cited by 80
Raut, S. B., Marathe, P. A., van Eijk, L., Eri, R. D., Ravindran, M., Benedek, D. M., Ursano, R. J., Canales, J. J., & Johnson, L. R. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108195 · Cited by 74
Intersection of Racism and PTSD: Assessment and Treatment of Racial Stress and Trauma
Williams, M. T., Osman, M., Gran-Ruaz, S., & Lopez, J. (2021) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-021-00250-2 · Cited by 68
A Review on Post-traumatic Stress Disorder (PTSD): Symptoms, Therapies and Recent Case Studies
Thakur, A., Choudhary, D., Kumar, B., & Chaudhary, A. (2021) · Current Molecular Pharmacology · doi:10.2174/1874467214666210525160944 · Cited by 72
Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry
Aday, J. S., Barnett, B. S., Grossman, D., Murnane, K. S., Nichols, C. D., & Hendricks, P. S. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0013 · Cited by 65
MDMA and MDMA-assisted therapy
Wolfgang, A. S., Fonzo, G. A., Gray, J. C., Krystal, J. H., Grzenda, A., Widge, A. S., Kraguljac, N. V., McDonald, W. M., Rodriguez, C. I., & Nemeroff, C. B. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230681 · Cited by 62
The emerging role of psilocybin and MDMA in the treatment of mental illness
Gill, H., Gill, B., Chen-Li, D. C. J., El‐Halabi, S., Rodrigues, N. B., Cha, D. S., Lipsitz, O., Lee, Y. L., Rosenblat, J. D., Majeed, A., et al. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1826931 · Cited by 63
Jones, G. M., & Nock, M. K. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211058923 · Cited by 65
Neitzke‐Spruill, L. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.022 · Cited by 61
Singewald, N., Sartori, S. B., Reif, A., & Holmes, A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109418 · Cited by 64
Psychedelic therapy: a roadmap for wider acceptance and utilization
Marks, M., & Cohen, I. G. (2021) · Nature Medicine · doi:10.1038/s41591-021-01530-3 · Cited by 59
The Emerging Field of Psychedelic Psychotherapy
Barber, G., & Aaronson, S. T. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01363-y · Cited by 68
Marseille, E. A., Kahn, J. G., Yazar‐Klosinski, B., & Doblin, R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239997 · Cited by 58
Maples‐Keller, J. L., Norrholm, S. D., Burton, M. S., Reiff, C. M., Coghlan, C., Jovanović, T., Yasinski, C. W., Jarboe, K. S., Rakofsky, J. J., Rauch, S. A. M., et al. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069124 · Cited by 58
Solmi, M., Chen, C., Dauré, C., Buot, A., Ljuslin, M., Verroust, V., Mallet, L., Khazaal, Y., Rothen, S., Thorens, G., et al. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.09.004 · Cited by 62
The economics of psychedelic-assisted therapies: A research agenda
Marseille, E. A., Bertozzi, S., & Kahn, J. G. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1025726 · Cited by 62
Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies
Studerus, E., Vizeli, P., Harder, S., Ley, L., & Liechti, M. E. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121998322 · Cited by 57
Sabé, M., Sulstarova, A., Glangetas, A., Pieri, M. D., Mallet, L., Curtis, L., Richard-Lepouriel, H., Penzenstadler, L. E., Seragnoli, F., Thorens, G., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02800-5 · Cited by 61
Agin-Liebes, G., Ekman, E., Anderson, B., Malloy, M., Haas, A., & Woolley, J. (2024) · Journal of Humanistic Psychology · doi:10.1177/00221678211022949 · Cited by 51
Illingworth, B. J. G., Lewis, D. J., Lambarth, A. T., Stocking, K., Duffy, J. M., Jelen, L. A., & Rucker, J. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120965915 · Cited by 59
Marseille, E., Mitchell, J. M., & Kahn, J. G. (2022) · PLOS ONE · doi:10.1371/journal.pone.0263252 · Cited by 50
Wolf, G., Singh, S., Blakolmer, K., Lerer, L. B., Lifschytz, T., Heresco‐Levy, U., Lotan, A., & Lerer, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01832-z · Cited by 51
Review of otential sychedelic reatments for PTSD
Henner, R. L., Keshavan, M. S., & Hill, K. P. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120302 · Cited by 60
Caution at psychiatry’s psychedelic frontier
Burke, M. J., & Blumberger, D. M. (2021) · Nature Medicine · doi:10.1038/s41591-021-01524-1 · Cited by 54
Jones, G. M., & Nock, M. K. (2022) · Scientific Reports · doi:10.1038/s41598-022-18645-3 · Cited by 48
Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms
Calder, A. E., Mock, S., Friedli, N., Pasi, P., & Hasler, G. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.05.008 · Cited by 52
Agnorelli, C., Spriggs, M. J., Godfrey, K., Sawicka, G., Bohl, B., Douglass, H. M., Fagiolini, A. M., Parastoo, H., Carhart-Harris, R. L., Nutt, D. J., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106132 · Cited by 65
Vizeli, P., Straumann, I., Duthaler, U., Varghese, N., Eckert, A., Paulus, M. P., Risbrough, V. B., & Liechti, M. E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.906639 · Cited by 47
Singleton, S. P., Wang, J. B., Mithoefer, M. C., Hanlon, C. A., George, M. S., Mithoefer, A., Mithoefer, O. J., Coker, A. R., Yazar‐Klosinski, B., Emerson, A., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.947622 · Cited by 46
MacKay, M., Yang, B. H., Dursun, S. M., & Baker, G. B. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230222092029 · Cited by 52
Posttraumatic Growth After MDMA‐Assisted Psychotherapy for Posttraumatic Stress Disorder
Gorman, I., Belser, A. B., Jerome, L., Hennigan, C., Shechet, B., Hamilton, S., Yazar‐Klosinski, B., Emerson, A., & Feduccia, A. A. (2020) · Journal of Traumatic Stress · doi:10.1002/jts.22479 · Cited by 44
The need for establishing best practices and gold standards in psychedelic medicine
Feduccia, A. A., Agin-Liebes, G., Price, C. M., Grinsell, N., Paradise, S., & Rabin, D. M. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.03.083 · Cited by 44
Ponté, L., Jerome, L., Hamilton, S., Mithoefer, M. C., Yazar‐Klosinski, B., Vermetten, E. H. G. J. M., & Feduccia, A. A. (2021) · Journal of Traumatic Stress · doi:10.1002/jts.22696 · Cited by 45
Bajor, L. A., Balsara, C., & Osser, D. N. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114840 · Cited by 43
Penn, A., Phelps, J., Rosa, W. E., & Watson, J. (2021) · Journal of Humanistic Psychology · doi:10.1177/00221678211011013 · Cited by 45
Yu, Z., Burback, L., Winkler, O., Xu, L., Dennett, L., Vermetten, E. H. G. J. M., Greenshaw, A. J., Li, X., Milne, M., Wang, F., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1386321 · Cited by 49
CE: Psychedelic-Assisted Therapy
Penn, A., Dorsen, C. G., Hope, S., & Rosa, W. E. (2021) · AJN American Journal of Nursing · doi:10.1097/01.naj.0000753464.35523.29 · Cited by 42
Oeri, H. E. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120920420 · Cited by 43
Feduccia, A. A., Jerome, L., Mithoefer, M. C., & Holland, J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05710-w · Cited by 40
RetractedSide-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis
Colcott, J., Guerin, A. A., Carter, O. L., Meikle, S. E., & Bedi, G. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01865-8 · Cited by 42
Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy
Thal, S. B., Bright, S. J., Sharbanee, J. M., Wenge, T., & Skeffington, P. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.617224 · Cited by 38
Jones, G. M., & Nock, M. K. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211066714 · Cited by 41
Healy, C. J., Lee, K. A., & D'Andrea, W. M. (2021) · Chronic Stress · doi:10.1177/24705470211029881 · Cited by 39
Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia
Glynos, N. G., Pierce, J. M., Davis, A. K., McAfee, J., & Boehnke, K. F. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.2022817 · Cited by 42
DePierro, J. M., Lepow, L., Feder, A., & Yehuda, R. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.07.009 · Cited by 41
Borissova, A., Ferguson, B., Wall, M. B., Morgan, C. J. A., Carhart-Harris, R. L., Bolstridge, M., Bloomfield, M., Williams, T. M., Feilding, A., Murphy, K., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120926673 · Cited by 39
Relational and Growth Outcomes Following Couples Therapy With MDMA for PTSD
Wagner, A. C., Liebman, R. E., Mithoefer, A. T., Mithoefer, M. C., & Monson, C. M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.702838 · Cited by 38
Sakurai, H., Yonezawa, K., Tani, H., Mimura, M., Bauer, M., & Uchida, H. (2022) · Pharmacopsychiatry · doi:10.1055/a-1714-9097 · Cited by 40
The Potential Role of Psychedelic Drugs in Mental Health Care of the Future
Gründer, G., & Jungaberle, H. (2021) · Pharmacopsychiatry · doi:10.1055/a-1486-7386 · Cited by 39
Ketamine-Assisted Psychotherapy for PTSD Related to Racial Discrimination
Halstead, M., Reed, S., Krause, R., & Williams, M. T. (2021) · Clinical Case Studies · doi:10.1177/1534650121990894 · Cited by 40
Sottile, R., & Vida, T. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.991753 · Cited by 41
Psilocybin and Other Classic Psychedelics in Depression
Nutt, D., Peill, J. M., Weiss, B., Godfrey, K., Carhart-Harris, R. L., & Erritzøe, D. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_451 · Cited by 39
Jahn, Z. W., Lopez, J., de la Salle, S., Faber, S. C., & Williams, M. T. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00166 · Cited by 35
Liechti, M. E., & Holze, F. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_270 · Cited by 37
MDMA and memory, addiction, and depression: dose-effect analysis
Pantoni, M. M., Kim, J. L., Alstyne, K. R. V., & Anagnostaras, S. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06086-9 · Cited by 41
Pharmacological Management of Nightmares Associated with Posttraumatic Stress Disorder
Geldenhuys, C., van den Heuvel, L. L., Steyn, P., & Seedat, S. (2022) · CNS Drugs · doi:10.1007/s40263-022-00929-x · Cited by 39
Ching, T. H. W., Davis, A. K., Xin, Y., & Williams, M. T. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2025960 · Cited by 38
Hussain, J. H., Gilbert, N., Costello, A., Schofield, C. J., Kemsley, E. K., Sutcliffe, O. B., & Mewis, R. E. (2020) · Forensic Chemistry · doi:10.1016/j.forc.2020.100263 · Cited by 33
Filippo, R. D., Rost, B. R., Stumpf, A., Cooper, C., Tukker, J. J., Harms, C., Beed, P. S., & Schmitz, D. (2021) · eLife · doi:10.7554/elife.66960 · Cited by 34
Tedesco, S., Gajaram, G., Chida, S., Ahmad, A., Pentak, M., Kelada, M., Lewis, L., Krishnan, D., Tran, C., Soetan, O. T., et al. (2021) · Cureus · doi:10.7759/cureus.15070 · Cited by 36
The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns
Johnston, C. B., Mangini, M., Grob, C. S., & Anderson, B. T. (2022) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2022.08.007 · Cited by 36
Embracing data preservation, sharing, and re-use in traumatic stress research
Kassam‐Adams, N., & Olff, M. (2020) · European Journal of Psychotraumatology · doi:10.1080/20008198.2020.1739885 · Cited by 33
MDMA for the Treatment of Negative Symptoms in Schizophrenia
Arnovitz, M. D., Spitzberg, A. J., Davani, A. J., Vadhan, N. P., Holland, J. A., Kane, J. M., & Michaels, T. I. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123255 · Cited by 31
Minorities’ diminished psychedelic returns
Viña, S. M., & Stephens, A. L. (2023) · Drug Science Policy and Law · doi:10.1177/20503245231184638 · Cited by 31
Jones, G. M., & Nock, M. K. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211058933 · Cited by 36
Gasparyan, A., Navarro, D., Navarrete, F., & Manzanares, J. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109211 · Cited by 34
Metadata
- Authors
- Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R.
- Affiliations
- Medical University of South Carolina (US)
- Multidisciplinary Association for Psychedelic Studies (US)
- University of British Columbia, Okanagan Campus (CA)
- Stanford Medicine (US)
- Corresponding author
- Feduccia, Allison A.
- Venue
- Psychopharmacology
- Published
- 2019-05-07
- Volume
- 236
- Issue
- 9
- Pages
- 2735-2745
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- PMC
- PMC6695343
- OpenAlex
- W2944263526
- Cited by
- 359
- References
- 39
- Citations by year
- 2026: 14 · 2025: 32 · 2024: 54 · 2023: 76 · 2022: 78 · 2021: 56 · 2020: 38 · 2019: 11
- FWCI
- 53.72
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- retraction (2024-08-10)
- Open access
- hybrid
- doi.org
- Locations
- Psychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Multidisciplinary Association for Psychedelic Studies (X)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- MDMA-assisted psychotherapy, MDMA, post-traumatic stress disorder, phase 3 trial design, treatment efficacy, depression symptom improvement, tolerability, breakthrough therapy designation
- MeSH terms
- Adult, Combined Modality Therapy, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Psychotherapy, Stress Disorders, Post-Traumatic, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Serotonin Agents, N-Methyl-3,4-methylenedioxyamphetamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
